Antibacterial Activity of Pasak Bumi Stem (Eurycoma longifolia J.) Extract against Salmonella typhi

Typhoid fever is caused by consuming food or water contaminated with Salmonella typhi. The disease develops from bacterial infection through the consumption of contaminated sustenance and drink. The bacterium can cause bacteremia, which is bacteria living in the blood, penetrating the mucosal epithelium of the small intestine and entering the lymphatic flow. Therefore, this study aimed to assess the potential inhibitory effect of ethanol extracts derived from stems of Eurycoma longifolia (pasak bumi) on the growth of Salmonella typhi bacteria. Compounds such as alkaloids, saponins, flavonoids, terpenoids, and tannins in pasak bumi stems possessed antibacterial properties. Extracts were made using 96% ethanol at varying concentrations (10%, 20%, 30%, 40%, 50%) with distilled water and chloramphenicol as negative and positive control. The result showed that pasak bumi stem extracts inhibited Salmonella typhi, with increasing efficacy at higher concentrations and statistical analysis reported significant differences between all treatment groups (p<0.001). Average zone diameter was 0 mm and 23.10 mm for negative and positive control, as well as 2.75 mm, 4.10 mm, 5.24 mm, 6.98 mm, and 8.55 mm for 10%, 20%, 30%, 40% and 50% extracts, respectively. This study provided verification of antibacterial effects of pasak bumi stem ethanol extracts against Salmonella typhi

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome